Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2000; 35:45-50
© 2000 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kukin, M. L.
Right arrow Articles by Ocampo, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kukin, M. L.
Right arrow Articles by Ocampo, O.

CLINICAL STUDIES

Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure

Marrick L. Kukin, MD, FACCa, Michael M. Mannino, MD, FACCa, Ronald S. Freudenberger, MD, FACCa, Jill Kalman, MDa, Cathleen Buchholz-Varley, NPa and Ofelia Ocampo, NPa

a Heart Failure Program, Cardiovascular Institute, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA

Manuscript received February 25, 1999; revised manuscript received July 9, 1999, accepted September 21, 1999.

Reprint requests and correspondence: Marrick Kukin, Cardiovascular Institute, Department of Medicine, Box 1030, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, New York 10029
marrick.kukin{at}mssm.edu

OBJECTIVES

To compare the hemodynamic effects of twice daily metoprolol tartrate (MT) and once daily metoprolol succinate (MS) in congestive heart failure patients.

BACKGROUND

Adverse hemodynamic effects with MT demonstrated during initiation persist with drug readministration during chronic therapy.

METHODS

Patients were randomly assigned to 6.25 mg MT or 25 mg MS orally and the dose was gradually increased to a target of 50 mg twice a day or 100 mg once a day, respectively. Hemodynamic measurements were obtained at baseline and after three months of therapy—both before and after drug readministration.

RESULTS

Long term metoprolol therapy produced significant functional, exercise and hemodynamic benefits with no difference in response between either metoprolol preparation in the 27 patients (MT [14], MS [13]). When full dose metoprolol was readministered during chronic therapy, there were parallel adverse hemodynamic effects in both drug groups. Cardiac index decreased by 0.6 liters/min/m2 (p < 0.0001) with MT and by 0.5 liters/min/m2 (p < 0.0001) with MS. Systematic vascular resistance increased by 253 dyne-sec-cm–5 (p < 0.001) with MT and by 267 dyne-sec-cm–5 (p < 0.0005) with MS. Stroke volume index decreased by 7.0 ml/m2 (p < 0.0005) with MT and by 6.5 ml/m2 (p < 0.0001) with MS, while SWI decreased by 6.2 g-m/m2 (p < 0.0005) with MT and by 6.0 g-m/m2 (p < 0.001) with MS.

CONCLUSION

Metoprolol tartrate and MS produce similar hemodynamic and clinical effects acutely and chronically despite the fourfold greater starting dose of MS used in this study. A more rapid initiation with readily available starting doses of MS may offer distinct advantages compared with MT in treating chronic heart failure patients with beta-adrenergic blocking agents.

Abbreviations and Acronyms
  b.i.d. = twice a day
  CI = cardiac index
  MERIT-HF = Metoprocol Randomized Intervention Trial
  MS = metoprolol succinate
  MT = metoprolol tartrate
  NYHA = New York Heart Association
  PCW = pulmonary capillary wedge pressure
  q.d. = every day
  SVI = stroke volume index
  SVR = systemic vascular resistance
  SWI = stroke work index




This article has been cited by other articles:


Home page
HypertensionHome page
C. H. Manisty, A. Zambanini, K. H. Parker, J. E. Davies, D. P. Francis, J. Mayet, S. A. McG Thom, A. D. Hughes, and on behalf of the Anglo-Scandinavian Cardiac Outcom
Differences in the Magnitude of Wave Reflection Account for Differential Effects of Amlodipine- Versus Atenolol-Based Regimens on Central Blood Pressure: An Anglo-Scandinavian Cardiac Outcome Trial Substudy
Hypertension, October 1, 2009; 54(4): 724 - 730.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. Metra, C. Torp-Pedersen, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, L. D. Cas, P. Spark, K. Swedberg, P. A. Poole-Wilson, et al.
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
Eur J Heart Fail, September 1, 2007; 9(9): 901 - 909.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. E. Sanderson, L. Y.C. Leung, S. K.W. Chan, G. W.K. Yip, J. W.H. Fung, and C.M. Yu
Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?
Eur J Heart Fail, August 1, 2005; 7(5): 874 - 877.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. L. Kukin
{beta}-Blockers in Chronic Heart Failure: Considerations for Selecting an Agent
Mayo Clin. Proc., November 1, 2002; 77(11): 1199 - 1206.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
M. Metra, S. Nodari, A. D'Aloia, C. Muneretto, A. D. Robertson, M. R. Bristow, and L. Dei Cas
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol
J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1248 - 1258.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement